Special access granted for lifesaving cholesterol drug in rare cases
NCT ID NCT06500598
Summary
This program provides special access to the drug evinacumab for patients with rare, severe inherited cholesterol or triglyceride disorders who have no other treatment options. It is for compassionate use, meaning it is considered on a case-by-case basis for individual patients who meet specific criteria. The goal is to help control these serious conditions and reduce the risk of heart disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.